Contrast with Australian Guidelines A/Pr Pascale Guitera,
|
|
- George Griffith
- 6 years ago
- Views:
Transcription
1 Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH
2 pages 16 pages lpracticeguidelines-managementofmelanoma.pdf new!!- with NOW constant updates
3 Level of evidence Intervention Diagnosis Prognosis Aetiology Screening
4 Prevention (2008) Environmental mel. risk is most strongly associated with an intermittent pattern of sun exposure, as in recreational exposure, and may be more potent when received in childhood and adolescence than in later life While robust conclusions are difficult at this time, the use of sunbeds and tanning booths is associated with a small increase in mel. risk. This risk may be more significant when exposure occurs before age 35 New evidence:zhang M. et al. Journal of clinical oncology 2012; 30 : 1-6 Cust AE, et al. International Journal of Cancer 2011;128: III-3 II Australian ban on tanning booth
5 Prevention (2) Brief sun exposures (for fair skinned individuals 6 8min in summer but 6 50min in winter depending on latitude) to around 15 20% body surface, most days are needed to maintain vit D levels, so total sun avoidance should not be practised without vit D supplementation. III-3 New evidence: controversial! Although sunscreens can reduce the risk of some non-mel. skin cancers, they have not conclusively been shown to reduce the risk of mel. III-3 New evidence: A C. Green et al J Clin Oncol 2011;29: Reduced mel. after regular sunscreen use: Randomized Trial Follow-Up. SUN CREAM DOES PROTECT
6 Population-based whole-body skin screening for mel. (2008) In the absence of substantive evidence as to its effectiveness in reducing mortality from mel., population-based skin screening cannot be recommended New evidence: Review JAAD 2017; 76:129-39: large ecological studies, a case control study and survey indicate benefit of skin cancer screening but evidence are very low Identification and management of high-risk individual High-risk individuals may benefit from regular clinical surveillance for new mel. and education to self-screen, based on expert opinion. There is no evidence to compare the relative effectiveness of specific surveillance techniques III-2
7 CDKN2A mutations cause high mel. risk in the context of familial mel., though their prevalence is low, even in that setting It is unclear at present whether individual risk management should be influenced by the results of genetic testing for CDKN2A mutations I IV Classification and staging of mel. = and new:ajcc 8thEdition: (activities +++ on new pronostic markers and new threshold for Breslow)
8 Clinical diagnosis (1) (new) NM, ALM and desmoplastic subtypes more commonly present as thick lesions and improved diagnostic accuracy of these is therefore critical. Nodular melanomas are associated with more rapid vertical growth compared to superficial spreading melanomas. Up to 20% of all melanomas are amelanotic or only partially pigmented, with this being more common amongst NM, ALM and desmoplastic subtypes. III-2, III-3, IV III-3, IV IV Scalp F70 nodular mel. Breslow 12mm Amelanosis/hypomelanosis is significantly associated with poorer diagnostic accuracy. III-2, III-3
9 Clinical diagnosis (2)- new From a meta-analysis of 9 level II studies prospectively performed in a clinical setting, the diagnostic accuracy for mel., as expressed by the relative diagnostic OR, was 15.6 times higher for DS compared with naked eye examination. Sensitivity of DS was 18% (95% CI 9% 27%; P=0.002) higher, but there was no evidence of an effect on specificity. 2 more level II studies showed results consistent with the larger meta-analysis. Ds reduce the benign:malignant ratio of excised melanocytic lesions and reduce the number of patients referred for biopsy in both specialists and primary care. I, II II
10 Sequential digital dermoscopic imaging (SDDI)-new 4level II studies and recent cohort studies show that SDDI allows the detection of suspicious dermoscopic change in mel. that lack dermoscopic evidence of mel. at a particular time. The routine use of SDDI in both specialist and primary care allows the detection of a significant proportion of patients mel. Long-term SDDI of multiple naevi in lower risk patients, while allowing detection of mel., is less efficacious. SDDI reduce the benign:malignant ratio of excised melanocytic lesions and reduce the number of patients referred for biopsy in both specialist and primary care. II, III-2 II, III-2 II No change=nevus 3months Change= early mel. 3months
11 Total body photo (2008) 8 level IV studies and 1 level III-3 study examined surveillance of high-risk subjects with TBP but only 1 included a comparison arm (of lower-risk subjects). All studies on high-risk patients showed early mel. detection and/or high mel. incidence. All studies were designed to assess the outcomes of surveillance in high-risk groups rather than the value of TBP
12 (In both systems: high false positive rates with seb.k. may cause a significantly poorer specificity when used by non-experts) Automated instrument- new To date, only 2 studies have been reported comparing specialist clinician diagnosis with an automated machine diagnosis with an adequate sample size to assess both specificity and sensitivity for the diagnosis of mel. II MelaFind System (Electro-Optical Sciences, Inc., USA), multispectral. Sensitivity of 98.3%, but a poor specificity of 9.9%,(higher than the study dermatologists) SciBase (Medtech, Sweden) electro-impedance:2 400 skin lesions (260 mel.), Nevisense overall sensitivity of 98% with 100% sensitivity on all stages of invasive mel.; Specificity 33%.
13 Biopsy- new Complete excision with a 2mm margin is the most reliable diagnostic biopsy method for skin lesions suspected of being mel. Punch biopsy has been shown in one large study to be associated with high rates of false negative histopathological diagnosis of 23% and should be used with caution for melanocytic lesions. Deep shave excision (saucerisation) is more likely to accurately stage the mel. if it is in situ or superficially invasive than if it is more deeply invasive. Partial biopsy has been shown to underestimate T-stage in 7-34% of punch biopsies and 3-19% of shave biopsies and provides insufficient information for appropriate surgical planning in 18% of punch biopsies and 3-5% of shave biopsies. Survival and the performance of sentinel node biopsy show no differences according to partial versus complete excisional biopsy type. III-2 III-2 III-2, IV III-2, IV III-2, IV
14 Similar Histopathological reporting Appropriate investigations Similar: none for stage I and II Regional LN ultrasonography > to palpation for the detection of regional LN metastasis Both LN ultrasonography and PET scanning < to SNB for the detection of occult LN metastasis II 1 III-2 New evidence: to be built as new adjuvant therapy introduced!
15 Treatment of primary mel. After initial excision biopsy; the radial excision margins, measured clinically from the edge of the mel.: (ptis) mel. in situ: margin 5mm (pt1) mel. < 1.0mm: 1cm (pt2) mel mm: 1 2cm (pt3) mel mm: 1 2cm (pt4) mel. > 4.0mm: 2cm New : There is case series evidence suggesting that 5 mm margins are often adequate to treat mel. in situ. However, in some cases they are inadequate and may lead to significant rates of disease recurrence. IV
16 SNB- new The status of the SN is the most significant predictor of mel.-specific survival for patients with mel. >1 mm Breslow. Overall, for patients with mel. >1 mm thick, SNB followed by immediate completion lymph node dissection for a positive node does not prolong melanoma specific survival or overall survival compared with not performing SNB (nodal observation) and delayed lymph node dissection for clinically detected nodes. For patients with intermediate thickness mel. ( mm thick) who harbour metastatic disease within the SN, early intervention with SNB may be associated with an increased mel. specific survival compared with nodal observation. Complication rates for SNB are low. The procedure should be performed in a centre with appropriate expertise as complication rates are inversely related to procedure volume - this particularly applies to primaries arising in the head & neck. III-3, IV II III-2 III-3
17 Follow-up (2008) Intervals between visits are mostly arbitrary. IV However, all studies stress that the more advanced the disease, the more frequent the visits need to be. US, only if performed by experienced ultrasonographers, is a useful adjunct to clinical examination in the follow-up of more advanced primary disease. No other tests have significant value in patients with localised disease New evidence: to be built as new efficient therapy introduced!
18 Lentigo maligna (2008) There are no prospective studies or randomised controlled trials available to form the basis of any recommendations for the management of LM IV
19 In summary, grading of recommendations «In clinical practice» Grade description A - Body of evidence can be trusted to guide practice B - Body of evidence can be trusted to guide practice in most situations C- Body of evidence provides some support for recommendation(s) but care should be taken in its application D - Body of evidence is weak and recommendation must be applied with caution
20 In summary (1) Prevention of mel. 1. Sunburn be avoided + UV protection B 2. Sunscreens be used to complement but not to replace physical methods C B 3. Risks associated with exposure to sunbeds be explained C B 4. As brief sun exposures are needed to maintain vit D levels, total lack of sun exposure is not advised without vit D supplementation C Population screening for mel.xx cannot be recommended C? x Identification and management of high-risk individuals High risk patient and their partner or carer be educated to recognise lesions suspicious, and to be regularly checked by a clinician with six-monthly full body examination supported by total body photography and dermoscopy as required C Good practice point Prophylactic removal of non-suspicious lesions is not recommended A
21 In summary (2) Identification and management of high-risk individuals continued... Screening for a genetic mutation such as the CDKN2A gene be contemplated only after a thorough clinical risk assessment, confirmation of a strong family history of mel. and appropriate genetic counselling C Classification of melanoma NEW AJCC/UICC B x Clinical diagnosis NEW Mel. are generally distinguished from benign lesions by their history of change and thick mel. often do not conform to the ABCD rule, but are Elevated, Firm and Growing. Therefore, careful history taking is important and any lesion that continues to grow or change in size, shape, colour or elevation over a period of more than 1 month should be biopsied ( ) Suspicious raised lesions should be excised and not monitored. C
22 In summary (3) 1- Clinicians who are performing skin examinations for the purpose of detecting skin cancer should be trained in and use dermoscopy. ( most GP in Australia) A 2- To assess individual melanocytic lesions of concern, recommend the use of short-term SDDI ( 3months) to detect mel. that lack dermoscopic features of melanoma. B - To assess individual or multiple melanocytic lesions in routine surveillance of high risk patients, recommend the use of long-term SDDI to detect mel. that lack dermoscopic features of melanoma. ( most GP in Australia) B (3- Consider the use of baseline total body photography as a tool for the early detection of mel. in patients who are at high risk )-not review NEW- Only flat or slightly raised lesions should undergo SDDI. - The interval for short-term monitoring is 3 months where any change leads to excision unlike >6months where certain specific changes are required for excision to be indicated. Where lentigo maligna is in the differential diagnosis 6 months is recommended
23 Biopsy-new In summary (4) 1. The optimal biopsy approach for a suspicious pigmented lesion is complete excision with a 2 mm clinical margin and upper subcutis. C 2. Partial biopsies may not be fully representative of the lesion and need to be interpreted with caution and in light of the clinical findings to minimise incorrect false negative diagnoses and understaging. C 3. In carefully selected clinical circumstances (such as large in situ lesions, large facial or acral lesions or where the suspicion of melanoma is low) and in the hands of experienced clinicians, partial incisional, punch or shave biopsies may be appropriate. C (Where a punch biopsy has been used for the diagnosis of a suspected BCC or SCC, and the diagnosis has been found to be melanocytic, then consideration should be given to excision of the entire lesion)
24 In summary (5) Histopathology (2008) The essential components of a histopathological report: Breslow thickness margins of excision (microscopic) mitotic rate/mm2 level of invasion (Clark) ulceration A (new: It is advisable to discuss unexpected pathology results with the reporting pathologist. ) Appropriate investigations (2008) The 6 recommendations are level D not detailed here as obsolete NEW: SNB should be considered for all patients with mel. >1 mm in thickness and for patients with mel. >0.75 mm with other high risk pathological features to provide optimal staging and prognostic information and to maximise management options for patients who are node positive.!!trials
25 In summary (6) In situ melanoma MARGIN of excision NEW: After initial excision biopsy, the radial excision margins, measured clinically from the edge of the mel., should be 5-10 mm (measured with good lighting and magnification) with the aim of achieving complete histological clearance. Melanoma in situ of non-lentigo maligna type is likely to be completely excised with 5mm margins whereas lentigo maligna may require wider excision. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.
26 In summary (7) Lentigo maligna- still Biopsy is indicated for changing pigmented lesions on the face C 2. Where LM is histologically confirmed, complete excision is the preferred management C 3. Radiotherapy is an alternative treatment option for patients where surgical excision is problematic or best avoided C x 4. Cryotherapy may occasionally be useful in patients with severe comorbidities or in those in whom surgery is not a possible option D x 5. Topical treatment modalities for LM cannot be recommended at this time C 2 New meta- analysis: RT around 12 % recurrence/ IQ around 25% x
27 Plenty of interesting topics! 9 Congenital melanocytic naevi 13 Management of locoregionally recurrent mel. 16 Psychosocial issues in mel. 18 Multidisciplinary care of mel. 21 Treatment of desmoplastic mel. 25 Mel. in children 26 Pregnancy and mel. (including hormone replacement therapy and oral contraceptives) 27 Prognostic factors and survival outcomes in cutaneous mel. -Managementofmelanoma.pdf
WHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationMelanoma. Consultation on draft guideline - stakeholder comments. Comments to be submitted before 5pm on Friday 13 March 2015
Please note: Please fill in both the stakeholder organisation and name of commentator fields. We cannot accept forms with attachments such as research articles, letters or leaflets. Stakeholder organisation(s)
More informationMelanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media
Melanoma and Dermoscopy Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery Medical Director, University Skin Clinic University of Texas
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationMalignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationDr. Brent Doolan, BSc MBBS MPH
Impact of partial biopsies on the need for complete excisional surgery in the management of cutaneous melanomas: A multi-centre review Dr. Brent Doolan, BSc MBBS MPH Peter MacCallum Cancer Centre, Melbourne
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationDavid B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma
Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past
More informationDiagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions Diagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19 NICE 2018. All rights reserved. Subject to Notice of
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationAn Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center
An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Assistant Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationThis is a repository copy of Easily missed? Amelanotic melanoma. White Rose Research Online URL for this paper:
This is a repository copy of Easily missed? Amelanotic melanoma. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/127789/ Version: Accepted Version Article: Muinonen-Martin,
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationCancer Council Australia Wiki Guidelines 2017
WHAT IS THE ROLE OF SEQUENTIAL DIGITAL DERMOSCOPY IMAGING IN MELANOMA DIAGNOSIS? Cancer Council Australia Wiki Guidelines 2017 SHORT-TERM MONITORING 3 months Any change leads to excision Any melanocytic
More informationManagement of Melanoma in Australia and New Zealand
Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand Approved by Evidence-based Best Practice Guideline Clinical Practice Guidelines for the Management of Melanoma
More informationMole mapping and monitoring. Dr Stephen Hayes. Associate Specialist in Dermatology, University Hospital Southampton
Mole mapping and monitoring Dr Stephen Hayes Associate Specialist in Dermatology, University Hospital Southampton Outline of presentation The melanoma epidemic Benefits of early detection Risks of the
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationClinical characteristics
Skin Cancer Fernando Vega, MD Seattle Healing Arts Clinical characteristics Precancerous lesions Common skin cancers ACTINIC KERATOSIS Precancerous skin lesions Actinic keratoses Dysplastic melanocytic
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationRare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham
Rare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham Classifying melanoma Melanoma (site of origin, thickness,
More informationDr Matthew Strack. Dermatologist Christchurch Dunedin Invercargill
Dr Matthew Strack Dermatologist Christchurch Dunedin Invercargill 14:00-14:55 WS #33: Managing Melanoma - Guidelines and Controversies 15:05-16:00 WS #43: Managing Melanoma - Guidelines and Controversies
More informationMELANOMA: HANDS-ON OR HANDS-OFF?
MELANOMA: HANDS-ON OR HANDS-OFF? M SCHAMM MBChB (Pret), FCS (SA) Endocrine and Transplant Surgeon, Department of Surgery, University of the Witwatersrand; and Clinical Head Transplant Surgery, Charlotte
More informationMELANOCYTIC LESIONS: EFFECTIVE MANAGEMENT IN PRIMARY CARE: Part 2
MELANOCYTIC LESIONS: EFFECTIVE MANAGEMENT IN PRIMARY CARE: Part 2 In the second part of our feature on pigmented skin lesions, dermatology specialist Dr Sweta Rai describes the steps to rational decision-making
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More information12. Malignant Melanoma of Skin
KEY FACTS 12. Malignant Melanoma of Skin ICD-9 172 On average 160 melanomas of the skin were registered per year. Twice as common in females than in males. Higher than expected numbers in Southern Board
More informationMalignant Melanoma Early Stage. A guide for patients
This melanoma patient brochure is designed to help educate melanoma patients and their caregivers. It was developed under the guidance of Dr. Michael Smylie, Professor, Department of Oncology, University
More informationOral and Maxillofacial Surgery Department
Oral and Maxillofacial Surgery Department This leaflet explains: Lentigo Maligna What are the aims of this leaflet? This leaflet has been written to help you understand more about lentigo maligna and melanoma
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationMelanoma: The Basics. What is a melanocyte?
Melanoma: The Basics What is a melanocyte? A melanocyte is a normal cell, found in the skin, which produces melanin. Melanin is a black or dark brown pigment that is seen in the skin, hair, and parts of
More informationWorld Articles of Ear, Nose and Throat Page 1
World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationDermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial
Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial Cutaneous Oncology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI
More informationSkin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationBACK TO TABLE OF CONTENTS FOCUS ON MELANOMA Oncology Annual Report BAPTIST HEALTH LEXINGTON ONCOLOGY ANNUAL REPORT
FOCUS ON MELANOMA 2014 Oncology Annual Report BAPTIST HEALTH LEXINGTON 1 2014 ONCOLOGY ANNUAL REPORT TABLE OF CONTENTS What is melanoma?...3 Who is at risk for melanoma?...3 What causes melanoma?...4 What
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Malignant melanoma: assessment and management of malignant melanoma 1.1 Short title Malignant Melanoma 2 The remit The Department
More informationMichael T. Tetzlaff MD, PhD
Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationProfessor Michael Eccles
Professor Michael Eccles Developmental Genetics & Pathology Laboratory Pathology Department University of Otago Dunedin 15:00-15:15 Melanoma Metastasis and Treatment Resistance Melanoma metastasis and
More informationLearning Objectives. Tanning. The Skin. Classic Features. Sun Reactive Skin Type Classification. Skin Cancers: Preventing, Screening and Treating
Learning Objectives Skin Cancers: Preventing, Screening and Treating Robert A. Baldor, MD, FAAFP Professor, Family Medicine & Community Health University of Massachusetts Medical School Distinguish the
More informationLarge majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.
Basics of Skin Cancer Detection and Treatment of Non- Melanoma Skin Cancers Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationPractical Tips for Caring for Melanoma Patients
Practical Tips for Caring for Melanoma Patients Caroline C. Kim, MD, Director Assistant Professor, Department of Dermatology Harvard Medical School Director, Pigmented Lesion Clinic Associate Director,
More informationDr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland
Dr Rosalie Stephens Medical Oncologist Auckland City Hospital Auckland Mr Richard Martin General Surgeon Melanoma Unit Team Waitemata District Health Board Auckland 8:30-9:25 WS #99: Interactive Case Studies
More informationDepartment of Dermatology, Queen Margaret & Victoria Hospitals
Department of Dermatology, Queen Margaret & Victoria Hospitals Management of primary skin cancer A copy of these local guidelines, national guidelines, information leaflets and other useful information
More informationSkin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1
Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer
More informationSkin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012
Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right
More informationSKIN CANCER. Most common cancer diagnosis 40% of all cancers
SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which
More informationIT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY
IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY Skin, Bones, and other Private Parts Symposium Dermatology Lectures by Debra Shelby, PhD, DNP, FNP-BC, FADNP, FAANP Debra Shelby,
More informationMalignant Melanoma Introduction increasing incidence increasing mortality skin >50% normal skin pigmented lesion
1 Malignant Melanoma Introduction Melanoma is a malignant tumor of melanocytes, cells that are derived from the neural crest. There is an increasing incidence of melanoma, as well as an increasing mortality,
More informationMetastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds
Metastatic Melanoma Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Case Presentation 77 year old male with previous history of scalp melanoma and thyroid
More informationEpidemiology. Objectives 8/28/2017
Case based Discussion of Head and Neck Melanoma: Review of Epidemiology, Risk Factors, Identification, Treatments and Prevention Jacqueline M. Doucette MS FNP-C Objectives Define and identify melanoma
More informationPeriocular Malignancies
Periocular Malignancies Andrew Gurwood, O.D., F.A.A.O., Dipl. Marc Myers, O.D., F.A.A.O. Drs. Myers and Gurwood have no financial interests to disclose. Course Description Discussion of the most common
More informationDiagnostics Assessment Programme
Diagnostics Assessment Programme Diagnostics Consultation Document: VivaScope 1500 and 3000 imaging systems for detecting and monitoring skin cancer lesions Evaluation Report NATIONAL INSTITUTE FOR HEALTH
More informationINTRODUCTION HOUSEKEEPING June 11 th Dr John Adams Dermatologist/Dermoscopist MOLEMAP NZ/Australia MOLESAFE USA
INTRODUCTION HOUSEKEEPING June 11 th 2015 Dr John Adams Dermatologist/Dermoscopist MOLEMAP NZ/Australia MOLESAFE USA Program Skin cancer statistics. Dermoscopy description and usefulness. Patient /lesion
More informationHauora Maori. Map. Non-Melanoma Skin Lesion. Clinically Seborrhoeic Keratosis. Management Options. Punch Biopsy. Refer to Public Skin Lesion Service
Care map information Information resources for patients and carers Updates to this Care Map Hauora Maori Pacific Skin lesion history Clinical examination and diagnostic test Suspicious of Melanoma Non-Melanoma
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationRacial differences in six major subtypes of melanoma: descriptive epidemiology
Wang et al. BMC Cancer (2016) 16:691 DOI 10.1186/s12885-016-2747-6 RESEARCH ARTICLE Racial differences in six major subtypes of melanoma: descriptive epidemiology Yu Wang 1, Yinjun Zhao 2 and Shuangge
More informationORAL MELANOMA Definition Epidemiology Clinical Presentation
ORAL MELANOMA Definition Melanoma is a highly malignant neoplasia, arising from melanocytes, the cells that produce the brownish pigment melanin. Melanin is the determinant in skin colour and protects
More informationPrinted by Martina Huckova on 10/3/2011 3:04:54 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
Table of Contents NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationDa Costa was the first to coin the term. Marjolin s Ulcer: A Case Report and Literature Review. Case Report. Introduction
E-Da Medical Journal 2016;3(2):24-28 Case Report Marjolin s Ulcer: A Case Report and Literature Review Yue-Chiu Su 1, Li-Ren Chang 2 Marjolin s ulcer is an aggressive cutaneous malignancy, which is common
More informationMalignant Melanoma Care Pathway
Malignant Melanoma Care Pathway Level 1-4 Community Skin Cancer Service Sussex Community Dermatology Service Version 3.0 Scope of Community Services for Malignant Melanoma All suspected cases of malignant
More informationAdvances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision
Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationCorporate Medical Policy
Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018
More informationClinical Case Conference Melanoma
Clinical Case Conference Melanoma Epidemiology ~60,000 cases and 8,000 deaths per year in US Caucasian:African American = 10:1 15% arise from existing nevi 91% are cutaneous 15% are LN+ at presentation
More informationGlenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine
Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment
More informationMultispectral Digital Skin Lesion Analysis. Summary
Subject: Multispectral Digital Skin Lesion Analysis Page: 1 of 8 Last Review Status/Date: March 2016 Multispectral Digital Skin Lesion Analysis Summary There is interest in noninvasive devices that will
More informationChallenges in Melanoma Diagnosis and Management
Challenges in Melanoma Diagnosis and Management Winter Clinical Dermatology Conference - Hawaii Darrell S. Rigel, MD MS Clinical Professor of Dermatology New York University Medical Center DISCLOSURE OF
More informationDermatological Manifestations in the Elderly. Sanjay Siddha Staff Dermatologist UHN & MSH
Dermatological Manifestations in the Elderly Sanjay Siddha Staff Dermatologist UHN & MSH Disclosure No actual or potential conflicts of interest or commercial relationships to declare Objectives Recognize
More informationNonmelanoma skin cancers
Skin cancer Philip Clarke Nonmelanoma skin cancers Treatment options Background Australia has one of the highest skin cancer rates in the world. Early detection and treatment of skin cancer is vital to
More informationIndex. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035
Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille
More informationManagement of Atypical Pigmented Lesions
Management of Atypical Pigmented Lesions Jennifer A. Stein MD, PhD Associate Director, Pigmented Lesion Section Ronald O. Perelman Department of Dermatology NYU Langone Medical Center July 29, 2017 1-4
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationLimitations of nonsurgical treatment modalities. Nonsurgical Treatments (Table V) 1/31/2018
DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY James M. Grichnik M.D. Ph.D. Alternative Therapies James M Grichnik MD PhD Director, Scully-Welsh Cancer Center Indian River Medical Center grichnik@irmc.cc
More informationTotal body photography in high risk patients
Total body photography in high risk patients Doug Grossman, MD, PhD Department of Dermatology Huntsman Cancer Institute University of Utah Summer AAD F032 Practical Considerations for Patients with Melanoma
More informationWhat is melanoma? Melanoma dealing with the diagnosis. What is melanoma?
Melanoma is a form of cancer which develops from that part of the skin which produces its colour. It grows from the cell which produces the brown pigment in our skin: the melanocyte. Often the melanoma
More informationVernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida
Vernon K. Sondak Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida Australasian Melanoma Conference 2016 Sydney, NSW, Australia October 29, 2016 Disclosures Dr. Sondak is a compensated
More informationSeventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Melanoma Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More information